Aldeyra Therapeutics (ALDX) said in a regulatory filing Wednesday that Chief Development Officer Stephen G. Machatha notified the company of his intent to resign to pursue other opportunities, effective around March 31.
Machatha's resignation did not stem from any disagreement with Aldeyra, the company said in its 8-K filing with the US Securities and Exchange Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments